Related Experiment Video
Updated: Jun 23, 2026
06:09
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Frequent mutations in the MITF pathway in melanoma
Julia C Cronin1, John Wunderlich, Stacie K Loftus
1National Human Genome Research Institute, Bethesda, MD, USA.
Pigment Cell & Melanoma Research
|May 9, 2009
Summary
Melanoma research reveals alterations in the Microphthalmia-associated transcription factor (MITF) pathway, including mutations and amplifications. These changes in MITF and its regulator SOX10 occur in over 20% of metastatic melanoma cases, impacting melanomagenesis.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Microphthalmia-associated transcription factor (MITF) is crucial for melanocyte development and is implicated in cancer.
- Understanding genetic alterations in MITF is vital for melanoma research.
Purpose of the Study:
- To investigate somatic mutations and genomic alterations of MITF in melanoma.
- To identify the role of MITF pathway dysregulation in melanoma development and progression.
Main Methods:
- Comparative sequencing of MITF from primary and metastatic melanoma lesions against patient-matched normal DNA.
- Analysis of MITF and SOX10 mutations, including amplifications, frameshift, and nonsense mutations.
- Assessment of alterations in both metastatic and primary melanoma samples.
Main Results:
- Genomic amplifications of MITF were found in 4/50 metastatic melanoma samples.
- MITF mutations were identified in 4/50 metastatic melanoma samples, affecting key functional domains.
- SOX10 mutations were found in 3/50 metastatic melanoma samples, and mutations in MITF and SOX10 occurred in a mutually exclusive manner.
- Overall, over 20% of metastatic melanoma cases showed alterations in the MITF pathway.
- Alterations were also observed in primary melanomas: 2/26 with MITF mutations and 6/55 with SOX10 mutations.
Conclusions:
- Altered MITF function, through amplification, mutation, or SOX10 dysregulation, is a significant factor in melanomagenesis.
- The MITF pathway is frequently dysregulated in both primary and metastatic melanoma.
- These findings highlight the MITF pathway as a potential therapeutic target in melanoma treatment.
More Related Videos
Related Concept Videos
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:07MAPK Signaling Cascades
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
02:21Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...